Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Elizabeth Olson Hexner, M.D., M.S.T.R.

Elizabeth Olson Hexner, M.D., M.S.T.R.

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215.614.1847
Fax: (215) 615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

Myeloproliferative Disorders
Umbilical Cord Blood Transplantation

Description of Clinical Expertise

Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Acute leukemia

Selected Publications

Babushok, D. V., Cardamone, D., Rulander, N., Master, S. R., Hexner, E. O.: A Common, Under-Recognized Cause of Elevated Serum Erythropoietin. Am J Med 2014.

Hexner, E: Essential Thrombocythemia. Rare Disease Database, National Organization for Rare Diseases (NORD) 2014 Notes: https://www.rarediseases.org/rare-disease-information/rare-diseases/byID/577/viewFullReport.

Babushok, D., Hexner, E.: Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin Hematol 21(2): 114-22, 2014.

Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., Hexner, E., Zhang, Y.: Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. J Immunol 2014.

Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation. Br J Haematol 164: 83–93, 2014.

Reshef, R., Hexner, E. O., Loren, A. W., Frey, N. V., Stadtmauer, E. A., Luger, S. M., Mangan, J. K., Gill, S. I., Vassilev, P., Lafferty, K. A., Smith, J., Van Deerlin, V. M., Mick, R., Porter, D. L.: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2014.

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013.

Kumar, A. J., Hexner, E. O., Frey, N. V., Luger, S. M., Loren, A. W., Reshef, R., Boyer, J., Smith, J., Stadtmauer, E. A., Levine, B. L., June, C. H., Porter, D. L., Goldstein, S. C.: Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19(7): 1094-101, 2013.

Lin, X., Rice, K. L., Buzzai, M., Hexner, E., Costa, F. F., Kilpivaara, O., Mullally, A., Soares, M. B., Ebert, B. L., Levine, R., Licht, J. D.: miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27: 344 - 52, 2013.

Kalota, A., Jeschke, G. R., Carroll, M., Hexner, E. O.: Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013.

back to top
Last updated: 08/27/2014
The Trustees of the University of Pennsylvania